{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"DGX","limit":50},"count":50,"signals":[{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":25,"context":"am members. Annually reviews the compensation arrangements for theCompanys executive leadership team members to assess whetherthe arrangements encourage risk taking that is reasonably likely to have amaterial adverse effect on the Company. Reviews and, if appropriate, approves or recommends to theBoard that it approve compensation related proposals to be votedupon by stockholders. Considers the results of stockholderadv","filed_date":"2026-04-06","accession":"0001140361-26-013356","full_text":"https://origin.rootz.global/static/filing/0001140361-26-013356.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":122,"context":"e per share |  | |  |  Meeting Agenda |  Board Recommendation |  | |  |  1. |  To elect eleven directors |  FOR EACH NOMINEE |  | |  |  2. |  To approve, on an advisory basis, the compensation of our named executive officers disclosed in our Proxy Statement |  FOR |  | |  |  3. |  To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2026 |  FOR |  | |  |  4. |  T","filed_date":"2026-04-06","accession":"0001140361-26-013356","full_text":"https://origin.rootz.global/static/filing/0001140361-26-013356.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":67,"context":"kely to be extensive.  The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability. The clinical testing business remains a fragmented and highly competitive industry. We primarily compete with three types of clinical testing providers: other comme","filed_date":"2026-02-26","accession":"0001022079-26-000015","full_text":"https://origin.rootz.global/static/filing/0001022079-26-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":25,"context":"f Executive Officer. Annually reviews the compensation arrangements for the Companys executive leadership team members to assess whether they encourage risk taking that is reasonably likely to have a material adverse effect on the Company. Reviews and, if appropriate, approves or recommends to the Board that it approve compensation related proposals to be voted upon by stockholders, and considers the results of stockhol","filed_date":"2025-04-04","accession":"0000930413-25-001171","full_text":"https://origin.rootz.global/static/filing/0000930413-25-001171.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":117,"context":"ne vote per share | | |  |  Meeting Agenda |  |  Board Recommendation | | |  1. |  To elect ten directors |  |  FOR EACH NOMINEE | | |  2. |  To approve, on an advisory basis, the compensation of our named executive officers disclosed in our Proxy Statement |  |  FOR | | |  3. |  To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025 |  |  FOR | | |  4. |  To","filed_date":"2025-04-04","accession":"0000930413-25-001171","full_text":"https://origin.rootz.global/static/filing/0000930413-25-001171.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":69,"context":"kely to be extensive.  The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability. The clinical testing business remains a fragmented and highly competitive industry. We primarily compete with three types of clinical testing providers: other comme","filed_date":"2025-02-20","accession":"0001022079-25-000044","full_text":"https://origin.rootz.global/static/filing/0001022079-25-000044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":31,"context":"f Executive Officer. Annually reviews the compensation arrangements for the Companys executive leadership team members to assess whether they encourage risk taking that is reasonably likely to have a material adverse effect on the Company. Reviews and, if appropriate, approves or recommends to the Board that it approve compensation related proposals to be voted upon by stockholders, and considers the results of stockhol","filed_date":"2024-04-05","accession":"0000930413-24-001247","full_text":"https://origin.rootz.global/static/filing/0000930413-24-001247.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":119,"context":"rs only: One vote per share | | |  |  Meeting Agenda |  Board Recommendation | | |  1. |  Elect nine directors |  FOREACHNOMINEE | | |  2. |  To approve, on an advisory basis, the compensation of our named executive officers disclosed in our Proxy Statement |  FOR | | |  3. |  To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2024 |  FOR | | |  4. |  To adopt","filed_date":"2024-04-05","accession":"0000930413-24-001247","full_text":"https://origin.rootz.global/static/filing/0000930413-24-001247.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":67,"context":"kely to be extensive.  The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability. The clinical testing business remains a fragmented and highly competitive industry. We primarily compete with three types of clinical testing providers: other comme","filed_date":"2024-02-22","accession":"0001022079-24-000041","full_text":"https://origin.rootz.global/static/filing/0001022079-24-000041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":25,"context":"entive compensation. Annually reviews the compensation arrangements for the Companys executive leadership team members to assess whether they encourage risk taking that is reasonably likely to have a material adverse effect on the Company. Annually reviews and, if appropriate, approves or recommends to the Board that it approve compensation related proposals to be voted upon by stockholders, and considers the results of","filed_date":"2023-04-06","accession":"0000930413-23-001199","full_text":"https://origin.rootz.global/static/filing/0000930413-23-001199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":133,"context":"only: One vote per share |  | | |  Meeting Agenda |  Board  Recommendation | | |  1. |  Elect ten directors |  FOR EACH NOMINEE | | |  2. |  To approve, on an advisory basis, the compensation of our named executive officers disclosed in our Proxy Statement |  FOR | | |  3. |  To recommend, on an advisory basis, the frequency of the stockholder advisory vote to approve executive officer compensation |  ANNUAL | | |  4.","filed_date":"2023-04-06","accession":"0000930413-23-001199","full_text":"https://origin.rootz.global/static/filing/0000930413-23-001199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":32,"context":"kely to be extensive.  The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability. The clinical testing business remains a fragmented and highly competitive industry. We primarily compete with three types of clinical testing providers: other comme","filed_date":"2023-02-21","accession":"0001022079-23-000018","full_text":"https://origin.rootz.global/static/filing/0001022079-23-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":19,"context":"incentive compensation. Annually reviews the compensation arrangements for the Companys senior management team members to assess whether they encourage risk taking that is reasonably likely to have a material adverse effect on the Company. Annually reviews and, if appropriate, approves or recommends to the Board that it approve compensation related proposals to be voted upon by stockholders, and considers the results of","filed_date":"2022-04-19","accession":"0000947871-22-000463","full_text":"https://origin.rootz.global/static/filing/0000947871-22-000463.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":101,"context":"ckholders only: One vote per share | | |  Meeting Agenda |  Board Recommendation | | |  1. Elect nine directors |  FOR EACH NOMINEE | | |  2. To approve, on an advisory basis, the compensation of our named executive officers disclosed in our Proxy Statement. |  FOR | | |  3. To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2022. |  FOR | | |  4. To adopt an a","filed_date":"2022-04-19","accession":"0000947871-22-000463","full_text":"https://origin.rootz.global/static/filing/0000947871-22-000463.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":33,"context":"kely to be extensive.  The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability. The clinical testing business remains a fragmented and highly competitive industry. We primarily compete with three types of clinical testing providers: other comme","filed_date":"2022-02-28","accession":"0001022079-22-000027","full_text":"https://origin.rootz.global/static/filing/0001022079-22-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":21,"context":"t determine the extent of any potential liability. Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the C","filed_date":"2021-10-22","accession":"0001022079-21-000144","full_text":"https://origin.rootz.global/static/filing/0001022079-21-000144.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":23,"context":"pensation. | | |  |  |  Annually reviews the compensation arrangements for the Companys senior management team members to assess whether they encourage risk taking that is reasonably likely to have a material adverse effect on the Company. | | |  |  |  Annually reviews and recommends to the Board the compensation of the Companys non-employee directors. | | |  |  |  Administers, or makes recommendations to the Board rega","filed_date":"2021-04-09","accession":"0000930413-21-000760","full_text":"https://origin.rootz.global/static/filing/0000930413-21-000760.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":105,"context":"Meeting |  |  AGAINST | | **Board Proposals** *Advisory Resolution to Approve Executive Officer Compensation*. We are asking our stockholders to approve, on an advisory basis, the compensation of our named executive officers disclosed in our 2021 proxy statement. *Ratify the Appointment of Independent Registered Public Accounting Firm for 2021*. We are asking our stockholders to ratify the selection of PricewaterhouseCo","filed_date":"2021-04-09","accession":"0000930413-21-000760","full_text":"https://origin.rootz.global/static/filing/0000930413-21-000760.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":34,"context":"kely to be extensive.  The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability. The clinical testing business remains a fragmented and highly competitive industry. We primarily compete with three types of clinical testing providers: other comme","filed_date":"2021-02-22","accession":"0001022079-21-000029","full_text":"https://origin.rootz.global/static/filing/0001022079-21-000029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":30,"context":"ion. |  6774 | | |  |  6.3 |  Enforceable Obligations. |  6775 | | |  |  6.4 |  No Conflicts. |  6775 | | |  |  6.5 |  Consents. |  6875 | | |  |  6.6 |  Financial Condition. |  6875 | | |  |  6.7 |  Material Adverse Effect. |  6876 | | |  |  6.8 |  Disclosure. |  6876 | | |  |  6.9 |  No Default. |  6976 | | |  |  6.10 |  Litigation. |  6976 | | |  |  6.11 |  Taxes. |  6976 | | |  |  6.12 |  Compliance with Law. |  697","filed_date":"2020-05-04","accession":"0000947871-20-000426","full_text":"https://origin.rootz.global/static/filing/0000947871-20-000426.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":10,"context":"t determine the extent of any potential liability. Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the C","filed_date":"2020-05-04","accession":"0001022079-20-000107","full_text":"https://origin.rootz.global/static/filing/0001022079-20-000107.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":23,"context":"incentive compensation. Annually reviews the compensation arrangements for the Companys senior management team members to assess whether they encourage risk taking that is reasonably likely to have a material adverse effect on the Company. Annually reviews and recommends to the Board the compensation of the Companys non-employee directors. Administers, or makes recommendations to the Board regarding, the equity-based, i","filed_date":"2020-04-08","accession":"0000947871-20-000354","full_text":"https://origin.rootz.global/static/filing/0000947871-20-000354.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":103,"context":"2020 |  FOR | | |  |  | | **Board Proposals** *Advisory Resolution to Approve Executive Officer Compensation*. We are asking our stockholders to approve, on an advisory basis, the compensation of our named executive officers disclosed in our 2020 proxy statement. *Ratify the Appointment of Independent Registered Public Accounting Firm for 2020*. We are asking our stockholders to ratify the selection of PricewaterhouseCo","filed_date":"2020-04-08","accession":"0000947871-20-000354","full_text":"https://origin.rootz.global/static/filing/0000947871-20-000354.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"restructuring","strength":100,"match_count":10,"context":"1, 2019, we incurred $60 million of pre-tax charges under our Invigorate program primarily consisting of systems conversion and integration costs, all of which result in cash expenditures. Additional restructuring charges may be incurred in future periods as we identify additional opportunities to achieve further cost savings. For further details of the Invigorate program and associated costs, see Note 5 to the audite","filed_date":"2020-02-20","accession":"0001022079-20-000017","full_text":"https://origin.rootz.global/static/filing/0001022079-20-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":42,"context":"kely to be extensive.  The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability. The clinical testing business remains a fragmented and highly competitive industry. We primarily compete with three types of clinical testing providers: other comme","filed_date":"2020-02-20","accession":"0001022079-20-000017","full_text":"https://origin.rootz.global/static/filing/0001022079-20-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":1,"context":"r relationships and technology, and approximately $70 million of goodwill.  Acquisition of the Outreach Laboratory Services Business of Memorial Hermann Health System On January 27, 2020, the Company entered into a definitive agreement to acquire the outreach laboratory services business of Memorial Hermann Health System (\"Memorial Hermann\"). Memorial Hermann is a not-for-profit health system in Southeast Texas. Closing of the tran","filed_date":"2020-02-20","accession":"0001022079-20-000017","full_text":"https://origin.rootz.global/static/filing/0001022079-20-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":17,"context":"determine the extent of any potential liability.  Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the C","filed_date":"2019-10-23","accession":"0001022079-19-000183","full_text":"https://origin.rootz.global/static/filing/0001022079-19-000183.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":25,"context":"determine the extent of any potential liability.  Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the C","filed_date":"2019-07-24","accession":"0001022079-19-000166","full_text":"https://origin.rootz.global/static/filing/0001022079-19-000166.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":90,"context":"oyee Plan) |  FOR |  54 | | **Board Proposals** Advisory Resolution to Approve Executive Officer Compensation. We are asking our stockholders to approve, on an advisory basis, the compensation of our named executive officers disclosed in our 2019 proxy statement. Ratify the Appointment of Independent Registered Public Accounting Firm for 2019. We are asking our stockholders to ratify the selection of PricewaterhouseCoop","filed_date":"2019-04-03","accession":"0000930413-19-001130","full_text":"https://origin.rootz.global/static/filing/0000930413-19-001130.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"restructuring","strength":100,"match_count":8,"context":"ployee separation costs and other restructuring related costs with the remainder primarily consisting of systems conversion and integration costs, all of which result in cash expenditures. Additional restructuring charges may be incurred in future periods as we identify additional opportunities to achieve further cost savings. For further details of the Invigorate program and associated costs, see Note 5 to the audite","filed_date":"2019-02-21","accession":"0001022079-19-000030","full_text":"https://origin.rootz.global/static/filing/0001022079-19-000030.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":22,"context":"rograms and the loss of various licenses, certificates and authorizations necessary to operate our business, as well as incur additional liabilities from third-party claims, all of which could have a material adverse effect on our business. Certain violations of these laws may also provide the basis for a civil remedy under the federal False Claims Act, including fines and damages of up to three times the amount claimed","filed_date":"2019-02-21","accession":"0001022079-19-000030","full_text":"https://origin.rootz.global/static/filing/0001022079-19-000030.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":1,"context":"PORATED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED (in millions unless otherwise indicated) 7.DISPOSITIONS Sale of Focus Diagnostics Products On March 29, 2016, the Company entered into a definitive agreement to sell the assets of its non-core Focus Diagnostics products business (\"Focus Diagnostics\") to DiaSorin S.p.A. (\"DiaSorin\"). On May 13, 2016, the Company completed the sale of Focus Diagnostics for","filed_date":"2019-02-21","accession":"0001022079-19-000030","full_text":"https://origin.rootz.global/static/filing/0001022079-19-000030.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"restructuring","strength":100,"match_count":11,"context":"of Contents](#sB18AAD2F361D248C57E1DC7F66D40B44) QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED (unaudited) (in millions, except per share data) Restructuring Charges The following table provides a summary of the Company's pre-tax restructuring charges for the three and ninemonths ended September30, 2018and 2017: | | | | | | | | | | | | | | | | | | | | | | | Three","filed_date":"2018-10-24","accession":"0001022079-18-000180","full_text":"https://origin.rootz.global/static/filing/0001022079-18-000180.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"restructuring","strength":100,"match_count":11,"context":"of Contents](#sBC7AC645C148DACB393BFD8023C2A873) QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED (unaudited) (in millions, except per share data) Restructuring Charges The following table provides a summary of the Company's pre-tax restructuring charges for the three and sixmonths ended June30, 2018and 2017: | | | | | | | | | | | | | | | | | | | | | | | Three Month","filed_date":"2018-07-25","accession":"0001022079-18-000163","full_text":"https://origin.rootz.global/static/filing/0001022079-18-000163.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"restructuring","strength":100,"match_count":10,"context":"ogram is driving the standardization of processes, information technology systems and equipment and data; digitization of the Company's services; and enhancement of reimbursement for work performed.  Restructuring Charges The following table provides a summary of the Company's pre-tax restructuring charges for the threemonths ended March31, 2018and 2017: | | | | | | | | | | | | | | | Three Months Ended March 31, | | |","filed_date":"2018-04-20","accession":"0001022079-18-000106","full_text":"https://origin.rootz.global/static/filing/0001022079-18-000106.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":88,"context":"olders |  AGAINST |  51 | | **Board Proposals** Advisory Resolution to Approve Executive Officer Compensation. We are asking our stockholders to approve, on an advisory basis, the compensation of our named executive officers disclosed in our 2018 proxy statement. Ratify the Appointment of Independent Registered Public Accounting Firm for 2018. We are asking our stockholders to ratify the selection of PricewaterhouseCoop","filed_date":"2018-04-04","accession":"0000930413-18-001188","full_text":"https://origin.rootz.global/static/filing/0000930413-18-001188.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"restructuring","strength":100,"match_count":9,"context":"150 million, or 50%, of our Senior Notes due April 2016 and all of our $375 million Senior Notes due July 2017; | | | | | | | | pre-tax charges of $110 million, or $0.46 per diluted share, related to restructuring costs primarily associated with workforce reductions, integration costs associated with acquisitions and professional fees associated with further restructuring and integrating our business ($63 million in","filed_date":"2018-02-23","accession":"0001022079-18-000038","full_text":"https://origin.rootz.global/static/filing/0001022079-18-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"growth_inflection","strength":100,"match_count":13,"context":"tables. | | | | | | | | Index to Tables | | | Table 1 - Vision, Goals and Values | 3 | | | Table 2 - Two Point Business Strategy | 3 | | | Table 3 - Portfolio Growth | 4 | | | Table 4 - Strategies to Accelerate Growth | 4 | | | Table 5 - Key Professional Laboratories Services Offerings | 5 | | | Table 6 - Clinical Franchises | 5 | | | Table 7 - Consumer-Centric Initiatives to Accelerate Growth | 6 | | | Table 8 -","filed_date":"2018-02-23","accession":"0001022079-18-000038","full_text":"https://origin.rootz.global/static/filing/0001022079-18-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":23,"context":"rograms and the loss of various licenses, certificates and authorizations necessary to operate our business, as well as incur additional liabilities from third-party claims, all of which could have a material adverse effect on our business. Certain federal and state statutes, regulations and other laws, including the qui tam 31 [Table of Contents](#s631A0B3E6744C25E29F95534C6B1B84F) provisions of federal and state false","filed_date":"2018-02-23","accession":"0001022079-18-000038","full_text":"https://origin.rootz.global/static/filing/0001022079-18-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":2,"context":"PORATED AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED (in millions unless otherwise indicated) 6.DISPOSITIONS Sale of Focus Diagnostics Products On March 29, 2016, the Company entered into a definitive agreement to sell the assets of its non-core Focus Diagnostics products business (\"Focus Diagnostics\") to DiaSorin S.p.A. (\"DiaSorin\"). On May 13, 2016, the Company completed the sale of Focus Diagnostics for","filed_date":"2018-02-23","accession":"0001022079-18-000038","full_text":"https://origin.rootz.global/static/filing/0001022079-18-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":86,"context":"ctor Plan) |  FOR |  51 | | **Board Proposals** Advisory Resolution to Approve Executive Officer Compensation. We are asking our stockholders to approve, on an advisory basis, the compensation of our named executive officers disclosed in our 2017 proxy statement. Advisory Vote Regarding the Frequency of the Advisory Vote to Approve Executive Officer Compensation. We are asking our stockholders to vote, on an advisory ba","filed_date":"2017-04-05","accession":"0000930413-17-001411","full_text":"https://origin.rootz.global/static/filing/0000930413-17-001411.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"restructuring","strength":100,"match_count":10,"context":"with the Invigorate program were $152 million, including approximately $50 million of cumulative pre-tax employee separation costs and other restructuring related costs. For further details regarding restructuring costs related to the Invigorate program, see Note 4 to the consolidated financial statements. Outlook and Trends The healthcare system in the United States is evolving; significant change is taking place i","filed_date":"2017-02-22","accession":"0001022079-17-000032","full_text":"https://origin.rootz.global/static/filing/0001022079-17-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":23,"context":"rograms and the loss of various licenses, certificates and authorizations necessary to operate our business, as well as incur additional liabilities from third-party claims, all of which could have a material adverse effect on our business. Certain federal and state statutes, regulations and other laws, including the qui tamprovisions of federal and state false claims acts, allow private individuals to bring lawsuits ag","filed_date":"2017-02-22","accession":"0001022079-17-000032","full_text":"https://origin.rootz.global/static/filing/0001022079-17-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":4,"context":"nder our secured receivables credit facility. For further details regarding our acquisitions, see Note 5 to the consolidated financial statements. Sale of Focus Diagnostics Products In March 2016, we signed a definitive agreement to sell the assets of our non-core Focus Diagnostics products business (\"Focus Diagnostics\") to DiaSorin S.p.A. On May 13, 2016, we completed the sale of Focus Diagnostics for $300 million in cash, o","filed_date":"2017-02-22","accession":"0001022079-17-000032","full_text":"https://origin.rootz.global/static/filing/0001022079-17-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":95,"context":"lan (the ESPP) | |  FOR | |  50 | | **Board Proposals** Advisory Resolution to Approve Executive Compensation. We are asking our stockholders to approve, on an advisory basis, the compensation of our named executive officers disclosed in our 2016 proxy statement. Ratify the Appointment of Independent Registered Public Accounting Firm for 2016. We are asking our stockholders to ratify the selection of PricewaterhouseCoop","filed_date":"2016-04-07","accession":"0000930413-16-006330","full_text":"https://origin.rootz.global/static/filing/0000930413-16-006330.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"restructuring","strength":100,"match_count":13,"context":"connection with the 2015 course of action were $89 million, including $39 million of cumulative pre-tax employee separation costs and other restructuring related costs. For further details regarding restructuring costs related to the Invigorate program, see Note 4 to the consolidated financial statements. Recent Transactions Acquisitions In 2015, we acquired MemorialCare Health System's laboratory outreach business","filed_date":"2016-02-26","accession":"0001022079-16-000195","full_text":"https://origin.rootz.global/static/filing/0001022079-16-000195.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":100,"match_count":14,"context":"rograms and the loss of various licenses, certificates and authorizations necessary to operate our business, as well as incur additional liabilities from third-party claims, all of which could have a material adverse effect on our business. Certain federal and state statutes, regulations and other laws, including the qui tamprovisions of federal and state false claims acts, allow private individuals to bring lawsuits ag","filed_date":"2016-02-26","accession":"0001022079-16-000195","full_text":"https://origin.rootz.global/static/filing/0001022079-16-000195.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"strategic_event","strength":100,"match_count":3,"context":"ratory outreach services business and the business assets of Superior Mobile Medics, Inc. (\"Superior Mobile Medics\"), which operated in the risk assessment business. In addition, we announced that we entered into a definitive agreement to acquire the outreach laboratory service business ofClinical Laboratory Partners. | | | | | | | | We entered into an agreement to provide professional lab services for Barnabas Health, New Jersey's","filed_date":"2016-02-26","accession":"0001022079-16-000195","full_text":"https://origin.rootz.global/static/filing/0001022079-16-000195.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"risk_factor","strength":98,"match_count":11,"context":"ot determine the extent of any potential liability.Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the C","filed_date":"2024-07-24","accession":"0001022079-24-000156","full_text":"https://origin.rootz.global/static/filing/0001022079-24-000156.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DGX","company":"QUEST DIAGNOSTICS INC","exchange":"NYSE","sector":"Services-Medical Laboratories","signal_type":"growth_inflection","strength":96,"match_count":12,"context":"tables. | | | | | | | | Index to Tables | | | Table 1 - Vision, Goals and Values | 2 | | | Table 2 - Two Point Business Strategy | 2 | | | Table 3 - Portfolio Growth | 3 | | | Table 4 - Strategies to Accelerate Growth | 3 | | | Table 5 - Key Professional Lab Services Offerings | 4 | | | Table 6 - Clinical Franchises | 4 | | | Table 7 - Consumer-Centric Initiatives to Accelerate Growth | 5 | | | Table 8 - 2016 Cons","filed_date":"2017-02-22","accession":"0001022079-17-000032","full_text":"https://origin.rootz.global/static/filing/0001022079-17-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"6539157629d2ed6f08573523e2e85f2639cb98a17c865e7a0b62ecc16c27d6ce","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"86db60b2e13fab7095e08952af073791350d4fc626647ba52d0e183f3afe9b6f","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":101,"hourly_limit":500,"remaining":399,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}